Personal tools

Coexpression cluster:C2826: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0007023!6.16e-53!115;UBERON:0001049!3.71e-38!57;UBERON:0005068!3.71e-38!57;UBERON:0006241!3.71e-38!57;UBERON:0007135!3.71e-38!57;UBERON:0003080!3.52e-34!42;UBERON:0001017!6.55e-34!82;UBERON:0005743!8.68e-34!86;UBERON:0002780!1.86e-33!41;UBERON:0001890!1.86e-33!41;UBERON:0006240!1.86e-33!41;UBERON:0000073!2.02e-33!94;UBERON:0001016!2.02e-33!94;UBERON:0002616!3.82e-31!59;UBERON:0003075!6.94e-29!86;UBERON:0007284!6.94e-29!86;UBERON:0000955!9.98e-29!69;UBERON:0006238!9.98e-29!69;UBERON:0002346!1.03e-27!90;UBERON:0002020!2.52e-27!34;UBERON:0003528!2.52e-27!34;UBERON:0001893!3.65e-27!34;UBERON:0001869!3.01e-26!32;UBERON:0002791!3.96e-26!33;UBERON:0003056!1.56e-24!61;UBERON:0004121!1.18e-22!169;UBERON:0000924!3.24e-22!173;UBERON:0006601!3.24e-22!173;UBERON:0002619!4.42e-22!22;UBERON:0001950!3.70e-20!20;UBERON:0000153!5.55e-20!129;UBERON:0007811!5.55e-20!129;UBERON:0000033!7.24e-20!123;UBERON:0000956!1.09e-19!25;UBERON:0000203!1.09e-19!25;UBERON:0000064!2.58e-11!219;UBERON:0002420!2.47e-09!9;UBERON:0007245!2.47e-09!9;UBERON:0010009!2.47e-09!9;UBERON:0010011!2.47e-09!9;UBERON:0000454!2.47e-09!9;UBERON:0002308!4.29e-09!9;UBERON:0000125!4.29e-09!9;UBERON:0000062!1.45e-08!511;UBERON:0000200!6.85e-08!6;UBERON:0001894!1.09e-07!7;UBERON:0006222!1.09e-07!7;UBERON:0002298!1.35e-07!8;UBERON:0000475!1.43e-07!365;UBERON:0004111!2.29e-07!241;UBERON:0009663!2.40e-07!7;UBERON:0001871!3.43e-07!7;UBERON:0000025!4.71e-07!194;UBERON:0000468!7.42e-07!659
|ontology_enrichment_uberon=UBERON:0007023!6.16e-53!115;UBERON:0001049!3.71e-38!57;UBERON:0005068!3.71e-38!57;UBERON:0006241!3.71e-38!57;UBERON:0007135!3.71e-38!57;UBERON:0003080!3.52e-34!42;UBERON:0001017!6.55e-34!82;UBERON:0005743!8.68e-34!86;UBERON:0002780!1.86e-33!41;UBERON:0001890!1.86e-33!41;UBERON:0006240!1.86e-33!41;UBERON:0000073!2.02e-33!94;UBERON:0001016!2.02e-33!94;UBERON:0002616!3.82e-31!59;UBERON:0003075!6.94e-29!86;UBERON:0007284!6.94e-29!86;UBERON:0000955!9.98e-29!69;UBERON:0006238!9.98e-29!69;UBERON:0002346!1.03e-27!90;UBERON:0002020!2.52e-27!34;UBERON:0003528!2.52e-27!34;UBERON:0001893!3.65e-27!34;UBERON:0001869!3.01e-26!32;UBERON:0002791!3.96e-26!33;UBERON:0003056!1.56e-24!61;UBERON:0004121!1.18e-22!169;UBERON:0000924!3.24e-22!173;UBERON:0006601!3.24e-22!173;UBERON:0002619!4.42e-22!22;UBERON:0001950!3.70e-20!20;UBERON:0000153!5.55e-20!129;UBERON:0007811!5.55e-20!129;UBERON:0000033!7.24e-20!123;UBERON:0000956!1.09e-19!25;UBERON:0000203!1.09e-19!25;UBERON:0000064!2.58e-11!219;UBERON:0002420!2.47e-09!9;UBERON:0007245!2.47e-09!9;UBERON:0010009!2.47e-09!9;UBERON:0010011!2.47e-09!9;UBERON:0000454!2.47e-09!9;UBERON:0002308!4.29e-09!9;UBERON:0000125!4.29e-09!9;UBERON:0000062!1.45e-08!511;UBERON:0000200!6.85e-08!6;UBERON:0001894!1.09e-07!7;UBERON:0006222!1.09e-07!7;UBERON:0002298!1.35e-07!8;UBERON:0000475!1.43e-07!365;UBERON:0004111!2.29e-07!241;UBERON:0009663!2.40e-07!7;UBERON:0001871!3.43e-07!7;UBERON:0000025!4.71e-07!194;UBERON:0000468!7.42e-07!659
|pathway_enrichment=0.00304771246409304;0.049893154907868;1;87;ErbB signaling pathway (KEGG):04012!0.00273243186435928;0.049893154907868;1;78;Phosphatidylinositol signaling system (KEGG):04070!0.00182162124290619;0.049893154907868;1;52;mTOR signaling pathway (KEGG):04150!0.00301268128634485;0.049893154907868;1;86;Apoptosis (KEGG):04210!0.00266236950886289;0.049893154907868;1;76;VEGF signaling pathway (KEGG):04370!0.00357318013031598;0.049893154907868;1;102;Toll-like receptor signaling pathway (KEGG):04620!0.00378336719680516;0.049893154907868;1;108;T cell receptor signaling pathway (KEGG):04660!0.00262733833111469;0.049893154907868;1;75;B cell receptor signaling pathway (KEGG):04662!0.00276746304210748;0.049893154907868;1;79;Fc epsilon RI signaling pathway (KEGG):04664!0.00332796188607861;0.049893154907868;1;95;Fc gamma R-mediated phagocytosis (KEGG):04666!0.00304771246409304;0.049893154907868;1;87;Progesterone-mediated oocyte maturation (KEGG):04914!0.0016814965319134;0.049893154907868;1;48;Type II diabetes mellitus (KEGG):04930!0.00147130946542423;0.049893154907868;1;42;Aldosterone-regulated sodium reabsorption (KEGG):04960!0.00154137182092062;0.049893154907868;1;44;Carbohydrate digestion and absorption (KEGG):04973!0.00248721362012191;0.049893154907868;1;71;Bacterial invasion of epithelial cells (KEGG):05100!0.00364324248581237;0.049893154907868;1;104;Chagas disease (American trypanosomiasis) (KEGG):05142!0.00371330484130877;0.049893154907868;1;106;Amoebiasis (KEGG):05146!0.00217193302038814;0.049893154907868;1;62;Colorectal cancer (KEGG):05210!0.00245218244237371;0.049893154907868;1;70;Renal cell carcinoma (KEGG):05211!0.00245218244237371;0.049893154907868;1;70;Pancreatic cancer (KEGG):05212!0.00182162124290619;0.049893154907868;1;52;Endometrial cancer (KEGG):05213!0.00227702655363273;0.049893154907868;1;65;Glioma (KEGG):05214!0.00311777481958943;0.049893154907868;1;89;Prostate cancer (KEGG):05215!0.00248721362012191;0.049893154907868;1;71;Melanoma (KEGG):05218!0.0025572759756183;0.049893154907868;1;73;Chronic myeloid leukemia (KEGG):05220!0.00203180830939536;0.049893154907868;1;58;Acute myeloid leukemia (KEGG):05221!0.00297765010859665;0.049893154907868;1;85;Small cell lung cancer (KEGG):05222!0.00189168359840258;0.049893154907868;1;54;Non-small cell lung cancer (KEGG):05223!0.00241715126462552;0.049893154907868;1;69;IL-5 Signaling Pathway (Wikipathways):WP127!0.0025572759756183;0.049893154907868;1;73;AMPK signaling (Wikipathways):WP1403!0.00304771246409304;0.049893154907868;1;87;MicroRNAs in cardiomyocyte hypertrophy (Wikipathways):WP1544!0.00154137182092062;0.049893154907868;1;44;IL-7 Signaling Pathway (Wikipathways):WP205!0.000840748265956701;0.049893154907868;1;24;IL-9 Signaling Pathway (Wikipathways):WP22!0.00241715126462552;0.049893154907868;1;69;Alpha6-Beta4 Integrin Signaling Pathway (Wikipathways):WP244!0.00297765010859665;0.049893154907868;1;85;Apoptosis (Wikipathways):WP254!0.00357318013031598;0.049893154907868;1;102;IL-3 Signaling Pathway (Wikipathways):WP286!0.00241715126462552;0.049893154907868;1;69;Kit Receptor Signaling Pathway (Wikipathways):WP304!0.00346808659707139;0.049893154907868;1;99;IL-6 Signaling Pathway (Wikipathways):WP364!0.00224199537588454;0.049893154907868;1;64;IL-4 signaling Pathway (Wikipathways):WP395!0.00269740068661108;0.049893154907868;1;77;IL-2 Signaling Pathway (Wikipathways):WP49!0.00301268128634485;0.049893154907868;1;86;Delta-Notch Signaling Pathway (Wikipathways):WP61!0.00357318013031598;0.049893154907868;1;102;Toll-like receptor signaling pathway (Wikipathways):WP75!0.00378336719680516;0.049893154907868;1;108;Signaling by Insulin receptor (Reactome):REACT_498!0.00182162124290619;0.049893154907868;1;52;Signaling by EGFR (Reactome):REACT_9417!0.00227702655363273;0.049893154907868;1;65;Signaling by PDGF (Reactome):REACT_16888!0.00157640299866882;0.049893154907868;1;45;Signaling by FGFR (Reactome):REACT_9470!0.00161143417641701;0.049893154907868;1;46;Interactions of the immunoglobulin superfamily (IgSF) member proteins (Reactome):REACT_23853!0.0025572759756183;0.049893154907868;1;73;Notch up reg. targets (Netpath):NetPath_3
}}
}}

Revision as of 15:00, 13 July 2012


Full id: C2826_Mast_medial_frontal_occipital_parietal_brain_olfactory



Phase1 CAGE Peaks

Hg19::chr5:67586544..67586558,+p7@PIK3R1
Hg19::chr5:67588391..67588411,+p13@PIK3R1
Hg19::chr5:67588419..67588430,+p29@PIK3R1
Hg19::chr6:147453079..147453129,-p1@ENST00000431143
p1@uc003qlv.2


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


p.valueFDRnGenesnPathwayName
0.003047712464093040.049893154907868187ErbB signaling pathway (KEGG):04012
0.002732431864359280.049893154907868178Phosphatidylinositol signaling system (KEGG):04070
0.001821621242906190.049893154907868152mTOR signaling pathway (KEGG):04150
0.003012681286344850.049893154907868186Apoptosis (KEGG):04210
0.002662369508862890.049893154907868176VEGF signaling pathway (KEGG):04370
0.003573180130315980.0498931549078681102Toll-like receptor signaling pathway (KEGG):04620
0.003783367196805160.0498931549078681108T cell receptor signaling pathway (KEGG):04660
0.002627338331114690.049893154907868175B cell receptor signaling pathway (KEGG):04662
0.002767463042107480.049893154907868179Fc epsilon RI signaling pathway (KEGG):04664
0.003327961886078610.049893154907868195Fc gamma R-mediated phagocytosis (KEGG):04666
0.003047712464093040.049893154907868187Progesterone-mediated oocyte maturation (KEGG):04914
0.00168149653191340.049893154907868148Type II diabetes mellitus (KEGG):04930
0.001471309465424230.049893154907868142Aldosterone-regulated sodium reabsorption (KEGG):04960
0.001541371820920620.049893154907868144Carbohydrate digestion and absorption (KEGG):04973
0.002487213620121910.049893154907868171Bacterial invasion of epithelial cells (KEGG):05100
0.003643242485812370.0498931549078681104Chagas disease (American trypanosomiasis) (KEGG):05142
0.003713304841308770.0498931549078681106Amoebiasis (KEGG):05146
0.002171933020388140.049893154907868162Colorectal cancer (KEGG):05210
0.002452182442373710.049893154907868170Renal cell carcinoma (KEGG):05211
0.002452182442373710.049893154907868170Pancreatic cancer (KEGG):05212
0.001821621242906190.049893154907868152Endometrial cancer (KEGG):05213
0.002277026553632730.049893154907868165Glioma (KEGG):05214
0.003117774819589430.049893154907868189Prostate cancer (KEGG):05215
0.002487213620121910.049893154907868171Melanoma (KEGG):05218
0.00255727597561830.049893154907868173Chronic myeloid leukemia (KEGG):05220
0.002031808309395360.049893154907868158Acute myeloid leukemia (KEGG):05221
0.002977650108596650.049893154907868185Small cell lung cancer (KEGG):05222
0.001891683598402580.049893154907868154Non-small cell lung cancer (KEGG):05223
0.002417151264625520.049893154907868169IL-5 Signaling Pathway (Wikipathways):WP127
0.00255727597561830.049893154907868173AMPK signaling (Wikipathways):WP1403
0.003047712464093040.049893154907868187MicroRNAs in cardiomyocyte hypertrophy (Wikipathways):WP1544
0.001541371820920620.049893154907868144IL-7 Signaling Pathway (Wikipathways):WP205
0.0008407482659567010.049893154907868124IL-9 Signaling Pathway (Wikipathways):WP22
0.002417151264625520.049893154907868169Alpha6-Beta4 Integrin Signaling Pathway (Wikipathways):WP244
0.002977650108596650.049893154907868185Apoptosis (Wikipathways):WP254
0.003573180130315980.0498931549078681102IL-3 Signaling Pathway (Wikipathways):WP286
0.002417151264625520.049893154907868169Kit Receptor Signaling Pathway (Wikipathways):WP304
0.003468086597071390.049893154907868199IL-6 Signaling Pathway (Wikipathways):WP364
0.002241995375884540.049893154907868164IL-4 signaling Pathway (Wikipathways):WP395
0.002697400686611080.049893154907868177IL-2 Signaling Pathway (Wikipathways):WP49
0.003012681286344850.049893154907868186Delta-Notch Signaling Pathway (Wikipathways):WP61
0.003573180130315980.0498931549078681102Toll-like receptor signaling pathway (Wikipathways):WP75
0.003783367196805160.0498931549078681108Signaling by Insulin receptor (Reactome):REACT_498
0.001821621242906190.049893154907868152Signaling by EGFR (Reactome):REACT_9417
0.002277026553632730.049893154907868165Signaling by PDGF (Reactome):REACT_16888
0.001576402998668820.049893154907868145Signaling by FGFR (Reactome):REACT_9470
0.001611434176417010.049893154907868146Interactions of the immunoglobulin superfamily (IgSF) member proteins (Reactome):REACT_23853
0.00255727597561830.049893154907868173Notch up reg. targets (Netpath):NetPath_3



Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0035030phosphoinositide 3-kinase complex, class IA0.00167785234899329
GO:0043559insulin binding0.00167785234899329
GO:0043125ErbB-3 class receptor binding0.00209731543624161
GO:0043560insulin receptor substrate binding0.00209731543624161
GO:0048009insulin-like growth factor receptor signaling pathway0.00215723873441994
GO:0017046peptide hormone binding0.00215723873441994
GO:0035014phosphoinositide 3-kinase regulator activity0.00215723873441994
GO:0005159insulin-like growth factor receptor binding0.00230704697986577
GO:0019903protein phosphatase binding0.00272651006711409
GO:0005545phosphatidylinositol binding0.00272651006711409
GO:0005942phosphoinositide 3-kinase complex0.00272651006711409
GO:0019902phosphatase binding0.00272651006711409
GO:0005158insulin receptor binding0.00272651006711409
GO:0046854phosphoinositide phosphorylation0.00272651006711409
GO:0042562hormone binding0.00272651006711409
GO:0046834lipid phosphorylation0.00272651006711409
GO:0008286insulin receptor signaling pathway0.00315831030398737
GO:0030258lipid modification0.00484712900820283
GO:0030384phosphoinositide metabolic process0.00706464146944542
GO:0006650glycerophospholipid metabolic process0.00806967082134867
GO:0032403protein complex binding0.00806967082134867
GO:0019207kinase regulator activity0.00930445393532642
GO:0044445cytosolic part0.0138605194047272
GO:0042277peptide binding0.0138745482705214
GO:0007169transmembrane receptor protein tyrosine kinase signaling pathway0.0138745482705214
GO:0006644phospholipid metabolic process0.0138745482705214
GO:0035091phosphoinositide binding0.0155978125776783
GO:0006643membrane lipid metabolic process0.0162991371045062
GO:0007167enzyme linked receptor protein signaling pathway0.0167785234899329
GO:0019899enzyme binding0.0167785234899329
GO:0005125cytokine activity0.0167785234899329
GO:0005543phospholipid binding0.0175125838926175
GO:0005829cytosol0.0285728385313857
GO:0008289lipid binding0.0285728385313857
GO:0044255cellular lipid metabolic process0.036816874400767
GO:0006629lipid metabolic process0.0440902311707681
GO:0005102receptor binding0.0470252131325957



Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
adult organism6.16e-53115
neural tube3.71e-3857
neural rod3.71e-3857
future spinal cord3.71e-3857
neural keel3.71e-3857
anterior neural tube3.52e-3442
central nervous system6.55e-3482
regional part of forebrain1.86e-3341
forebrain1.86e-3341
future forebrain1.86e-3341
regional part of nervous system2.02e-3394
nervous system2.02e-3394
regional part of brain3.82e-3159
neural plate6.94e-2986
presumptive neural plate6.94e-2986
brain9.98e-2969
future brain9.98e-2969
neurectoderm1.03e-2790
gray matter2.52e-2734
brain grey matter2.52e-2734
telencephalon3.65e-2734
cerebral hemisphere3.01e-2632
regional part of telencephalon3.96e-2633
pre-chordal neural plate1.56e-2461
ectoderm-derived structure1.18e-22169
ectoderm3.24e-22173
presumptive ectoderm3.24e-22173
regional part of cerebral cortex4.42e-2222
neocortex3.70e-2020
anterior region of body5.55e-20129
craniocervical region5.55e-20129
head7.24e-20123
cerebral cortex1.09e-1925
pallium1.09e-1925
organ part2.58e-11219
basal ganglion2.47e-099
nuclear complex of neuraxis2.47e-099
aggregate regional part of brain2.47e-099
collection of basal ganglia2.47e-099
cerebral subcortex2.47e-099
nucleus of brain4.29e-099
neural nucleus4.29e-099
organ1.45e-08511
gyrus6.85e-086
diencephalon1.09e-077
future diencephalon1.09e-077
brainstem1.35e-078
organism subdivision1.43e-07365
anatomical conduit2.29e-07241
telencephalic nucleus2.40e-077
temporal lobe3.43e-077
tube4.71e-07194
multi-cellular organism7.42e-07659


Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs



JASPAR motifs

Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}



ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data


No analysis results for this cluster

Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data


This analysis result is provided for C0 - C305 clusters.